Company intelligence / Profile preview

Santalis Pharmaceuticals, Inc.

San Antonio, Texas, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Santalis developed both OTC and prescription products using East Indian Sandalwood Oil. Their Phase 2 study for atopic dermatitis showed that EISO was safe, well-tolerated, and efficacious for patients aged between 3 months and 12 years with mild, moderate or severe eczema. Their East Indian sandalwood oil product for atopic dermatitis reached the "Discontinued" phase according to available information[2][7].

Therapeutic areas: GastroenterologyDermatologyInfectious Diseases
Modalities: Botanical pharmaceuticalsspecifically East Indian Sandalwood Oil (EISO)
Industry: Biotech

Drug pipeline

4 assets

east indian sandalwood oil cream

3 more assets in the full pipeline.

Request access →

Partnerships

Galderma (Nestle-owned company)

Beyond the preview

Go deeper on Santalis Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Santalis Pharmaceuticals, Inc..

Explore the full profile